Intervacc AB (IVACC) AI Stock Analysis

• Market Cap: €332.29M
• Dividend Yield: N/A
• Average Volume (3M): 431.81K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.83
• Revenue Growth: 56.48%
• EPS Growth: 40.18%
• Country: SE
• Employees: 15
• Sector: Healthcare
• Sector Strength: 52
• Industry: Biotechnology
• EPS (TTM): -0.08
• Shares Outstanding: 340,813,200
• 10 Day Avg. Volume: 412,656
• 30 Day Avg. Volume: 431,814
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €1.01
• Price Target Upside: -1.45% Downside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 48 Neutral
• Price Target: kr1.00 ▼(-1.96% Downside)

Intervacc AB's overall stock score is primarily impacted by its financial performance, which shows significant profitability challenges despite revenue growth. The technical analysis suggests a bearish trend, while the valuation is unattractive due to negative earnings and no dividend yield. These factors collectively result in a below-average stock score.

Intervacc AB Business Overview & Revenue Model

Company Description

Intervacc AB (publ), a biotechnology company, engages in the research and development of vaccines for bacterial infections in animal health care. The company devlops vaccines for horses, piglets, and dairy cows. It offers Strangvac, a vaccine for equine strangles. The company also markets and sells veterinary medicines; and provides diagnostic services in veterinary bacteriology for veterinary clinics and stud farms. In addition, it is developing vaccines against streptococcus suis and staphylococcus aureus-infections. It serves customers in Nordic countries and the Baltic states. The company is based in Hägersten, Sweden.

How the Company Makes Money

Intervacc AB generates revenue primarily through the commercialization of its veterinary vaccines. The company's revenue model includes the direct sale of vaccines to veterinary clinics, distributors, and animal healthcare providers. Key revenue streams include sales from its lead product, Strangvac, a vaccine designed to combat strangles in horses. Additionally, Intervacc may earn income through strategic partnerships and collaborations with other biotechnology firms and research institutions, which can provide funding, milestone payments, and royalty agreements based on the successful development and commercialization of new vaccines. Licensing agreements for their proprietary technology platforms also constitute a potential revenue source.

Intervacc AB Financial Statement Overview

Summary

Intervacc AB faces significant profitability challenges despite revenue growth, as indicated by negative margins and returns. The balance sheet is strong with low leverage, but cash flow issues persist, requiring attention to operational efficiency. The company should focus on cost management and improving operational cash flows to enhance financial health.

Income Statement

Intervacc AB has shown a mixed performance on its income statement. The company has experienced revenue growth from 2020 to TTM (Trailing-Twelve-Months), but gross profit remains negative, indicating cost issues. Net profit margins are negative due to high costs relative to revenue. EBIT and EBITDA margins also reflect operational challenges, impacting profitability.

Balance Sheet

The balance sheet of Intervacc AB is relatively stable with a strong equity position and very low debt levels, leading to a favorable debt-to-equity ratio. However, the return on equity is negative due to persistent net losses, demonstrating inefficiencies in generating returns from equity.

Cash Flow

Intervacc AB's cash flow shows negative free cash flow, indicating cash outflows exceed the cash generated from operations. However, the company has improved its cash position significantly through financing activities. The operating cash flow to net income ratio suggests operational cash flow challenges.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	11.79M	8.02M	9.68M	5.24M	4.78M
Gross Profit	-3.53M	-13.81M	3.37M	6.25M	4.64M
EBITDA	-58.75M	-68.98M	-57.73M	-23.15M	-19.39M
Net Income	-75.52M	-102.85M	-64.16M	-29.38M	-25.60M
Balance Sheet
Total Assets	187.32M	259.61M	265.04M	329.39M	355.28M
Cash, Cash Equivalents and Short-Term Investments	34.40M	88.34M	45.70M	115.71M	164.25M
Total Debt	145.00K	181.00K	322.00K	433.00K	383.00K
Total Liabilities	24.99M	21.68M	14.88M	21.14M	17.67M
Stockholders Equity	162.33M	237.93M	250.16M	308.25M	337.61M
Cash Flow
Free Cash Flow	-53.90M	-47.94M	-75.92M	-48.67M	-31.50M
Operating Cash Flow	-53.20M	-45.83M	-69.79M	-25.46M	-20.08M
Investing Cash Flow	-706.00K	-2.11M	-6.13M	-23.13M	-11.27M
Financing Cash Flow	-36.00K	90.58M	5.91M	50.00K	143.06M

Intervacc AB Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.02
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:IVACC, the sentiment is Negative. The current price of 1.02 is below the 20-day moving average (MA) of 1.06, above the 50-day MA of 1.01, and below the 200-day MA of 1.17, indicating a neutral trend. The MACD of -0.01 indicates Positive momentum. The RSI at 47.47 is Neutral, neither overbought nor oversold. The STOCH value of 40.20 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:IVACC.

Intervacc AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.77B	-0.12	-39.07%	2.21%	22.68%	-1.42%
IVACC	48 Neutral	€332.29M	―	-24.61%	―	56.48%	40.18%
7XB	―	€39.12M	―	-47.73%	―	―	―
8E8	―	€25.47M	―	-57.25%	―	―	―
7ZA	―	€48.25M	―	-138.29%	―	―	―
6IRA	―	€23.36M	―	-194.31%	―	―	―
1YG0	―	€35.63M	―	-18.79%	―	―	―